- Conditions
- HIV Infections
- Interventions
- Placebo, TUTI-16 (0.03mg), TUTI-16 (0.1mg), TUTI-16 (0.6mg)
- Other · Biological
- Lead sponsor
- Thymon, LLC
- Industry
- Eligibility
- 18 Years to 50 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2010
- U.S. locations
- 1
- States / cities
- San Francisco, California
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 25–48
of 24
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Acute HIV Infection
- Interventions
- Nucleic Acid Amplification Testing
- Other
- Lead sponsor
- University of California, San Diego
- Other
- Eligibility
- 13 Years and older
- Enrollment
- 22,607 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2015
- U.S. locations
- 5
- States / cities
- San Diego, California
- Conditions
- Cutaneous Leishmaniasis
- Interventions
- Combination of autoclaved leishmania antigen with recombinant human interleukin-12 (rhIL-12) and aluminum hydroxide gel as adjuvants
- Biological
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- Not listed
- Enrollment
- 50 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 1999 – 2001
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Meningococcal Meningitis, Meningococcal Infections
- Interventions
- meningococcal meningitis conjugate vaccine, quadrivalent
- Biological
- Lead sponsor
- JN-International Medical Corporation
- Industry
- Eligibility
- 18 Years to 50 Years
- Enrollment
- 60 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2011 – 2013
- U.S. locations
- 1
- States / cities
- Hanford, California
- Conditions
- Zika Virus, Zika Virus Infection
- Interventions
- VLA1601, Placebo
- Biological
- Lead sponsor
- Valneva Austria GmbH
- Industry
- Eligibility
- 18 Years to 49 Years
- Enrollment
- 67 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018
- U.S. locations
- 1
- States / cities
- Knoxville, Tennessee
- Conditions
- Long COVID
- Interventions
- Minimal-Dose Home-Based Resistance Exercise
- Behavioral
- Lead sponsor
- VA Office of Research and Development
- Federal
- Eligibility
- 50 Years and older
- Enrollment
- 21 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 1
- States / cities
- Washington D.C., District of Columbia
- Conditions
- Neonatal Staphylococcal Sepsis
- Interventions
- Pagibaximab (formerly BSYX-A110)
- Drug
- Lead sponsor
- Biosynexus Incorporated
- Industry
- Eligibility
- 3 Days to 7 Days
- Enrollment
- 53 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2001 – 2003
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Mycobacterium Avium-intracellulare Infection, HIV Infections
- Interventions
- Ethambutol hydrochloride, Clarithromycin, Azithromycin
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 13 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- U.S. locations
- 24
- States / cities
- Berkeley, California • Mill Valley, California • Oakland, California + 17 more
- Conditions
- MRSA, VRE
- Interventions
- Not listed
- Lead sponsor
- University of Maryland, Baltimore
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 19,856 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2013
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Post-infectious Irritable Bowel Syndrome, Irritable Bowel Syndrome
- Interventions
- Not listed
- Lead sponsor
- University of Nevada, Reno
- Other
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 81 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024
- U.S. locations
- 1
- States / cities
- Reno, Nevada
- Conditions
- Sexually Transmitted Diseases, Gonorrhea, Chlamydia, Syphilis, HIV
- Interventions
- Motivational interviewing and specimen self-collection
- Behavioral
- Lead sponsor
- University of Michigan
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 75 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2025
- U.S. locations
- 1
- States / cities
- Ann Arbor, Michigan
- Conditions
- Covid19, SARS-CoV Infection, ARDS, ARDS, Human
- Interventions
- Instilled T3, Placebo Therapy
- Drug · Other
- Lead sponsor
- University of Minnesota
- Other
- Eligibility
- 18 Years to 80 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2031
- U.S. locations
- 1
- States / cities
- Minneapolis, Minnesota
- Conditions
- Post-Acute COVID-19 Syndrome
- Interventions
- Baricitinib 4 MG, Placebo
- Drug
- Lead sponsor
- Vanderbilt University Medical Center
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2029
- U.S. locations
- 6
- States / cities
- San Francisco, California • New Haven, Connecticut • Atlanta, Georgia + 2 more
- Conditions
- COVID-19, Vaccine-Preventable Diseases, SARS CoV 2 Infection
- Interventions
- protein subunit: Novavax COVID-19 vaccine, Pfizer mRNA COVID-19 vaccine
- Biological
- Lead sponsor
- Novavax
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 660 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2025
- U.S. locations
- 1
- States / cities
- Salt Lake City, Utah
- Conditions
- Cervical Cancer, Papilloma Viral Infection
- Interventions
- Stage 1 SOC, Stage 1 HERS, Stage 2 HERS, Stage 2 HERS+HC, Stage 3 SOC, Stage 3 HERS, Stage 3 HERS+HC, Stage 4 HERS, Stage 4 HERS+HC
- Behavioral
- Lead sponsor
- Fox Chase Cancer Center
- Other
- Eligibility
- 18 Years to 90 Years · Female only
- Enrollment
- 546 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2027
- U.S. locations
- 3
- States / cities
- New Brunswick, New Jersey • Philadelphia, Pennsylvania
- Conditions
- Acute Bacterial Skin and Skin Structure Infections
- Interventions
- sodium fusidate, linezolid
- Drug
- Lead sponsor
- Arrevus Inc.
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 716 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2016
- U.S. locations
- 60
- States / cities
- Anaheim, California • Bakersfield, California • Buena Park, California + 46 more
- Conditions
- Mycobacterium Avium-Intracellulare Infection
- Interventions
- Cytokine therapy, Interferon Gamma, GM-CSF
- Procedure · Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 2 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2010
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Appendicitis
- Interventions
- Appy CDS
- Other
- Lead sponsor
- HealthPartners Institute
- Other
- Eligibility
- 5 Years to 20 Years
- Enrollment
- 5,940 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2017 – 2019
- U.S. locations
- 2
- States / cities
- Oakland, California • Minneapolis, Minnesota
- Conditions
- Chediak-Higashi Syndrome
- Interventions
- Not listed
- Lead sponsor
- National Human Genome Research Institute (NHGRI)
- NIH
- Eligibility
- 1 Month to 70 Years
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2002
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- HIV Infections
- Interventions
- Zidovudine, Zalcitabine
- Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 13 Years and older
- Enrollment
- 112 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Ends 1991
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Nephrolithiasis, Urinary Tract Infection (UTI), Sepsis
- Interventions
- Nitrofurantoin 100 MG, 7d, Gentamicin, 5mg/kg, Ampicillin 2g, Nitrofurantoin 100 mg, 48 hrs, Gentamicin, 80 mg, 7d, Gentamicin, 80 mg, 48hr
- Drug
- Lead sponsor
- University of California, San Diego
- Other
- Eligibility
- Not listed
- Enrollment
- 330 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2025
- U.S. locations
- 1
- States / cities
- San Diego, California
- Conditions
- Cellulitis, Abscess, Drain Abscess, Impetigo, Skin Infection, Antibiotic Duration, Behavioral Economics
- Interventions
- Default Duration order Panel
- Behavioral
- Lead sponsor
- Nationwide Children's Hospital
- Other
- Eligibility
- 3 Months to 99 Years
- Enrollment
- 1,634 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2025
- U.S. locations
- 1
- States / cities
- Columbus, Ohio
- Conditions
- Clostridium Difficile
- Interventions
- Stool specimen
- Other
- Lead sponsor
- University of North Carolina, Chapel Hill
- Other
- Eligibility
- 1 Year to 99 Years
- Enrollment
- 34 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2020
- U.S. locations
- 1
- States / cities
- Chapel Hill, North Carolina
- Conditions
- Congenital Cytomegalovirus Infection
- Interventions
- Letermovir
- Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 0 Days to 90 Days
- Enrollment
- 3 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2026
- U.S. locations
- 3
- States / cities
- Birmingham, Alabama • Atlanta, Georgia • Milwaukee, Wisconsin